Journal article icon

Journal article

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

Abstract:

BACKGROUND

CD47 is a novel therapeutic target in the treatment of solid‐organ and hematologic malignancies. CD47 is also expressed on RBCs. Here, we report our experience of the RBC effects and the impact on blood bank testing and transfusion management in a Phase 1 trial of the humanized anti‐CD47 monoclonal antibody Hu5F9‐G4 in relapsed or primary refractory acute myeloid leukemia (AML) (NCT02678338).

STUDY DESIGN AND METHODS

Ninete...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1111/trf.15397

Authors


More by this author
Role:
Author
ORCID:
0000-0002-4028-3733
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM Strategic
Oxford college:
St Anne's College
Role:
Author
ORCID:
0000-0003-3931-0914
Expand authors...
Publisher:
Wiley Publisher's website
Journal:
Transfusion Journal website
Volume:
59
Issue:
7
Pages:
2248-2254
Publication date:
2019-06-10
Acceptance date:
2019-04-01
DOI:
EISSN:
1537-2995
ISSN:
0041-1132
Pmid:
31183877
Source identifiers:
1012664
Language:
English
Keywords:
Pubs id:
pubs:1012664
UUID:
uuid:3822e025-6475-4585-9b1c-424ab04d51a0
Local pid:
pubs:1012664
Deposit date:
2019-06-25

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP